机构:[1]Coriell Institute for Medical Research, Camden, NJ 08103, USA.[2]Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA 19104, USA.[3]Laboratory of Molecular Biology, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892, USA.[4]IPHASE Therapeutic Ltd., Philadelphia, PA 19454, USA.[5]Department of Pulmonary and Critical Care Medicine, Xuanwu Hospital Capital Medical University, Beijing 100053, China.首都医科大学宣武医院[6]Center for Metabolic Disease Research, Temple University Lewis Katz School of Medicine, Philadelphia, PA 19140, USA.[7]Cooper Medical School of Rowan University, Camden, NJ 08103, USA.
This work was supported by the funding from IPHASE
Therapeutic and a seed grant to J.H. from Coriell Institute
for Medical Research.
语种:
外文
被引次数:
WOS:
PubmedID:
第一作者:
第一作者机构:[1]Coriell Institute for Medical Research, Camden, NJ 08103, USA.
共同第一作者:
通讯作者:
通讯机构:[1]Coriell Institute for Medical Research, Camden, NJ 08103, USA.[4]IPHASE Therapeutic Ltd., Philadelphia, PA 19454, USA.[5]Department of Pulmonary and Critical Care Medicine, Xuanwu Hospital Capital Medical University, Beijing 100053, China.[6]Center for Metabolic Disease Research, Temple University Lewis Katz School of Medicine, Philadelphia, PA 19140, USA.[7]Cooper Medical School of Rowan University, Camden, NJ 08103, USA.[*1]Coriell Institute for Medical Research, 403 Haddon Avenue, Camden, NJ 08103, USA[*2]Department of Pulmonary and Critical Care Medicine, Xuanwu Hospital Capital Medical University, 45 Changchun St, Xicheng District, Beijing 100053, China[*3]Iphase Pharma Services LLC., 422 Industrial Dr, North Wales, PA, 19454, USA.
推荐引用方式(GB/T 7714):
Han Jianzhong,Liu Xiaolei,Xu Yue,et al.Characterization of HZ0412a, a novel potent humanized anti-IL-6 receptor antibody that blocks IL-6R binding to gp130[J].Antibody therapeutics.2023,6(2):119-126.doi:10.1093/abt/tbad008.
APA:
Han Jianzhong,Liu Xiaolei,Xu Yue,Wang Qian,Li Li...&Huang Jian.(2023).Characterization of HZ0412a, a novel potent humanized anti-IL-6 receptor antibody that blocks IL-6R binding to gp130.Antibody therapeutics,6,(2)
MLA:
Han Jianzhong,et al."Characterization of HZ0412a, a novel potent humanized anti-IL-6 receptor antibody that blocks IL-6R binding to gp130".Antibody therapeutics 6..2(2023):119-126